Chemotherapeutic targeting of cancer-induced immunosuppressive cells

Darya Alizadeh, Nicolas Larmonier

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppressor cells accumulate in the tumor microenvironment, secondary lymphoid tissues, and in the blood. Equipped with the ability to suppress innate and adaptive anticancer immunity, these cells also foster disease development by promoting tumor neoangiogenesis and by enhancing cancer metastasis. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. Recent work has provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced antitumor immunity. We analyze findings pertinent to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer chemoimmunotherapeutic strategies.

Original languageEnglish (US)
Pages (from-to)2663-2668
Number of pages6
JournalCancer Research
Volume74
Issue number10
DOIs
StatePublished - May 15 2014

Fingerprint

Immunosuppressive Agents
Neoplasms
Tumor Escape
Tumor Microenvironment
Cytostatic Agents
Adaptive Immunity
Lymphoid Tissue
Regulatory T-Lymphocytes
Cellular Structures
Antineoplastic Agents
Immune System
Immunity
Animal Models
Neoplasm Metastasis
Therapeutics
Pharmaceutical Preparations
Myeloid-Derived Suppressor Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapeutic targeting of cancer-induced immunosuppressive cells. / Alizadeh, Darya; Larmonier, Nicolas.

In: Cancer Research, Vol. 74, No. 10, 15.05.2014, p. 2663-2668.

Research output: Contribution to journalArticle

@article{064796fa8e654ecdb40eb6807f22e7e1,
title = "Chemotherapeutic targeting of cancer-induced immunosuppressive cells",
abstract = "The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppressor cells accumulate in the tumor microenvironment, secondary lymphoid tissues, and in the blood. Equipped with the ability to suppress innate and adaptive anticancer immunity, these cells also foster disease development by promoting tumor neoangiogenesis and by enhancing cancer metastasis. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. Recent work has provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced antitumor immunity. We analyze findings pertinent to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer chemoimmunotherapeutic strategies.",
author = "Darya Alizadeh and Nicolas Larmonier",
year = "2014",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-14-0301",
language = "English (US)",
volume = "74",
pages = "2663--2668",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Chemotherapeutic targeting of cancer-induced immunosuppressive cells

AU - Alizadeh, Darya

AU - Larmonier, Nicolas

PY - 2014/5/15

Y1 - 2014/5/15

N2 - The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppressor cells accumulate in the tumor microenvironment, secondary lymphoid tissues, and in the blood. Equipped with the ability to suppress innate and adaptive anticancer immunity, these cells also foster disease development by promoting tumor neoangiogenesis and by enhancing cancer metastasis. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. Recent work has provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced antitumor immunity. We analyze findings pertinent to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer chemoimmunotherapeutic strategies.

AB - The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppressor cells accumulate in the tumor microenvironment, secondary lymphoid tissues, and in the blood. Equipped with the ability to suppress innate and adaptive anticancer immunity, these cells also foster disease development by promoting tumor neoangiogenesis and by enhancing cancer metastasis. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. Recent work has provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced antitumor immunity. We analyze findings pertinent to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer chemoimmunotherapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84901281224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901281224&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0301

DO - 10.1158/0008-5472.CAN-14-0301

M3 - Article

C2 - 24778417

AN - SCOPUS:84901281224

VL - 74

SP - 2663

EP - 2668

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -